Abstract
Introduction: The presence of circulating tumor cells (CTC) is an independent prognostic factor for progressionfree survival and breast cancer-related death (BRD) for patients with metastatic breast cancer beginning a new line of systemic therapy The current study was undertaken to explore whether the presence of CTC at the time of diagnosis was associated with recurrence-free survival (RFS) and BRD.